Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Communications
Publications
Investor Presentations
In the News
Posters
Publications
Contact Us
Contact Us
Email Alerts
Media
Recent Posts
Entitlement Offer to raise $4.27m
Proactive Interview with Dr Chris Burns
FDA clearance of Amplia's IND for pancreatic cancer trial in US
First patient dosed in phase 2a ACCENT trial
Investor Newsletter - December 2023
Categories
Company News
Media
Uncategorized
Videos
28 Feb 2023
ACCENT Trial Recruitment Progress | Cohort 2 filled
Read More
13 Feb 2023
Women in Science | Q&A with Dr Terrie-Anne Cock, Head of Translational Biology
Read More
09 Feb 2023
35th Annual Lorne Cancer Conference, 9-11 February 2023
Read More
06 Feb 2023
Channel 9 News | 3 February 2023
Read More
06 Feb 2023
The Courier Mail | New hope for advanced pancreatic cancer patients in clinical trials
Read More
06 Feb 2023
ABC Media Coverage | Pancreatic cancer clinical trial opens in Queensland, offering hope to patients
Read More
01 Feb 2023
First Patient Recruited to Cohort 2 of ACCENT Trial in Pancreatic Cancer
Read More
1